ERBB2 and breast cancer: A 2022 population-based cohort study evaluating women with T1a/bN0M0 HER2+ BC reported that there was a 5-year disease-free survival of 94.8% in women who received adjuvant trastuzumab in comparison to 82.7% in women who did not receive trastuzumab (6).